United Kingdom
Veterinary Medicines Directorate
Woodham Lane
New Haw
Addlestone
Surrey KT15 3LS

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Plenix LC 75 mg, Intramammary Ointment for Lactating Cows [AT BE BG HR CY CZ EE FR DE EL HU IE IT LV LT PL PT RO SK SI UK]

Plenix Lactación 75 mg, intramammary ointment for lactating cows [ES]

Date Created: August 2017

PuAR correct as of 18/12/2018 when RMS was transferred to FR.
Please contact the RMS for future updates.

MODULE 1

PRODUCT SUMMARY

EU Procedure number	UK/V/0597/001/DC
Name, strength and pharmaceutical form	Plenix LC 75 mg, Intramammary Ointment for Lactating Cows
Applicant	Ceva Animal Health Ltd Unit 3, Anglo Office Park White Lion Road Amersham Buckinghamshire HP7 9FB
Active substance(s)	Cefquinome (as sulfate)
ATC Vetcode	QJ51DE90
Target species	Cattle
Indication for use	Lactating cows: For the treatment of clinical mastitis caused by the following cefquinome-sensitive microorganisms: *Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus* and *Escherichia coli*.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Product Information Database of the Veterinary Medicines Directorate.

(www.gov.uk/check-animal-medicine-licensed)

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article (13) 1 of Directive 2001/82/EC as amended.
Date of conclusion of the decentralised procedure	24th May 2017
Date product first authorised in the Reference Member State (MRP only)	Not applicable.
Concerned Member States for original procedure	Austria, Belgium, Bulgaria. Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain

I. SCIENTIFIC OVERVIEW

This was a generic application submitted according to Article (13) 1 of Directive 2001/82/EC, as amended. The product is Plenix LC 75 mg, Intramammary Ointment for Lactating Cows, for which the reference product was Cobactan LC 75 mg Intramammary Ointment, marketed in the UK since March 1996.

The proposed product is indicated for use in lactating cattle, for the treatment of clinical mastitis caused by the following cefquinome-sensitive microorganisms: *Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus* and *Escherichia coli*. The content of one syringe should be infused gently into the teat of the infected quarter every 12 hours after each of three successive milkings. Each syringe of 8 g contains 75 mg cefquinome, as sulfate.

The product is produced and controlled using validated methods and tests which ensure the consistency of the product released onto the market. It has been shown that the product can be safely used in the target species, any reactions observed are indicated in the SPC.[1] The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC. The efficacy [2] of the product was demonstrated according to the claims made in the SPC. The overall benefit/risk analysis is in favour of granting a marketing

[1] SPC – Summary of Product Characteristics.
[2] Efficacy – The production of a desired or intended result.

authorisation.

II. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTIUENTS

II.A. Composition

The product contains 75 mg cefquinome, as sulphate per 8 g syringe, and the excipients white soft paraffin and liquid paraffin.

The container/closure system consists of:

A pre-filled 8 g syringe consisting of white opaque high density polyethylene (HDPE) cylinders with white opaque low density polyethylene (LDPE) plungers and white opaque (HDPE) cap.

Cleaning towel (30% viscose / 70% polyester, alcohol impregnated) in a paper aluminium copolymer laminate sachet.

Pack of 3 syringes and 3 cleaning towels.

Pack of 15 syringes and 15 cleaning towels.

Pack of 20 syringes and 20 cleaning towels.

Pack of 24 syringes and 24 cleaning towels Pack of 60 syringes and 60 cleaning towels. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the formulation and the absence of preservative are justified. The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

II.B. Description of the Manufacturing Method

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site. The manufacturing method consists of: blending of the two excipients, sterile filtration, addition of the active substance, homogenisation and filling of the product into the syringes.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

II.C. Control of Starting Materials

The active substance is cefquinome sulphate sterile, micronized is an established active substance, the specification for which was provided by the Marketing Authorisation Holder. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The excipients and packaging comply with monographs in the European Pharmacopoeia.

II.C.4. Substances of Biological Origin

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

II.D. Control Tests Carried Out at Intermediate Stages of the Manufacturing Process

Not applicable.

II.E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product. Satisfactory validation data for the analytical methods have been provided. Batch analytical data from the proposed production sitehave been provided demonstrating compliance with the specification. Control tests on the finished product include those for: appearance of product, deliverable mass, density, particle size, viscosity, water content, identity of the active substance and related substances, sterility.

II.F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions. The retest period for the active substance is 2 years.

For the finished product, VICH[3] tests were performed on product stored at 25°C/60% RH, 30°C/65% RH and 40°C/75% RH, over a variety of time periods. No changes to the product were noted in photostability or freeze-thaw cycling studies. As this is a single dose product, no in-use stability studies were required.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Do not store above 30°C.

[3] VICH – Veterinary International Conference on Harmonisation.

III. SAFETY AND RESIDUES DOCUMENTATION (PHARMACO-TOXICOLOGICAL)

III.A Safety Documentation

Due to the legal basis of the application, toxicological and pharmacological data were not required.

User Safety

A user risk assessment was provided in compliance with the relevant guideline, in which it was proposed that as the proposed product is identical to the reference product no further data are required. This was accepted.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product. Therefore the following applicant's user recommendations are appropriate:

- When infusing the product, protective gloves should be worn to avoid skin contact.
- Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.
- Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
- Handle this product with great care to avoid exposure, taking all recommended precautions.
- If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.
- The cleaning towels provided with this product contain isopropyl alcohol, which may cause skin irritation in some people. It is recommended to wear protective gloves when using the towels.

Environmental Safety

The Environmental Risk Assessment (ERA) was carried out in accordance with VICH and CVMP guidelines.

The product will be used in food-producing, terrestrial species, reared indoors as well as on pasture. The PECsoil (predicted environmental concentration of the veterinary medicinal product in soil), was shown to be less than 100 µg/kg, and therefore the ERA stopped at Phase I.

III.B.2 Residues documentation

Residue Studies

No residue depletion studies were conducted because the proposed product was deemed to be bioequivalent to the reference product in accordance with EMA/CVMP/016/00-Rev.2, section 7.1, d). The applicant performed a comparison of the formulations of the proposed product and reference product. Nothing was found that would affect the pharmacokinetic properties of the proposed product. Depletion of residues can be considered comparable between the reference product and proposed product, and it was assumed that residue completion profiles are the same.

MRLs

As stated by the Committee for Veterinary Medicinal Products, the following MRLs were defined for bovine species:

Pharmacologically active substance	Marker residue	Animal species	MRLs (µg/kg)	Target tissues	Other provisions
Cefquinome	Cefquinome	Bovine	50 µg/kg	Muscle	
			50 µg/kg	Fat	
			100 µg/kg	Liver	
			200 µg/kg	Kidney	
			20 µg/kg	Milk	

Withdrawal Periods

Based on the data provided, anwithdrawal period of 4 days for meat and offal and 5 days (120 hours) for milk was agreed.

IV CLINICAL DOCUMENTATION

IV.I. Pre-Clinical Studies

As this was a generic application in accordance with Article (13) 1 of Directive 2001/82/EC as amended, and bioequivalence was accepted on the basis of essential similarity, no data were required for this section.

IV.II. Clinical Documentation

As this was a generic application in accordance with Article (13) 1 of Directive 2001/82/EC as amended, and bioequivalence was accepted on the basis of essential similarity, no data were required for this section.

V OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that <when the product is used in accordance with the Summary of Product Characteristics> the benefit/risk profile of the product(s) is favourable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)

The post-authorisation assessment (PAA) contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

The PAA for this product is available on the Product Information Database of the Veterinary Medicines Directorate website.

(www.gov.uk/check-animal-medicine-licensed)